All News

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.

The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.

The position statement is meant to iterate AUGS' support for gender inclusion of both patients and health care providers.

Cefepime-taniborbactam is currently under review by the FDA for cUTI, including acute pyelonephritis, based on data from the CERTAIN-1 trial.

The purpose of this clinical consensus statement is to identify areas of expert consensus and nonconsensus regarding pessary fitting, follow-up, and management of pessary complications to improve the safety and quality of care where evidence is currently limited.

Iterum plans to resubmit a New Drug Application for oral sulopenem for the treatment of patients with uUTi in Q2 of 2024.

The goals of the American Urogynecologic Society (AUGS) program are to support novel clinical, translational, and bench research pilot projects and enable early career investigators to obtain future independent funding for research.

There are several new CPT codes for 2024, including Category III codes for tibial nerve stimulation and other changes to codes in the treatment of urinary incontinence.

NRX-101 is a fixed-dose combination of the broad-spectrum antibiotic D-cycloserine and lurasidone.

Amy Luckenbaugh, MD, is an assistant professor of Urology at Vanderbilt University Medical Center.

The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs.

Hadley Wood, MD, shares her vision as the new editor-in-chief of Urology.

"I'm thrilled to continue my partnership with SMPA to educate and empower others to address their OAB," says Holly Robinson Peete.

“This study confirms what many women who’ve struggled with persistent UTIs already know, which is that the current methods of diagnosing and treating these infections are inadequate," says Jennifer Rohn, PhD.

“Sexual wellness is critical to overall health and happiness. That’s why you see more men and women turning to specialty health clinics for solutions to problems they consider more aesthetic versus medical,” said Mitchell Hollander, MD.

Using a case-based, interactive approach, this course is designed to offer practical clinical and surgical pearls for the management of women with complex pelvic floor disorders and complications.

“These findings demonstrate that electrofulguration provides a durable clinical cure that enables many postmenopausal women to remain UTI-free with minimal to no continued need for antibiotic therapy," says Philippe E. Zimmern, MD.

Increased retrovesicourethral angle, decreased functional urethral length, and the presence of bladder funnel were pelvic floor parameters identified as potential predictors of stress urinary incontinence in the early postpartum period.

“Patients who are candidates for bariatric surgery should be advised that improvement in urinary incontinence may also be a significant benefit of their intervention,” the authors wrote.

"As the number of women urologists continues to increase, the field of urology must pay attention to their needs and professional satisfaction as they will constitute an increasing proportion of the future urologic work force," writes Lourdes Guerrios Rivera, MD, MSc.

The incidence of 12-month surgical repair failure was 19% among those who received vaginal estrogen, compared with 9% among those who received placebo.

The new drug application is supported by findings from the phase 3 CERTAIN-1 trial.

Join Dr. Catherine Bradley, urogynecologist at the University of Iowa Hospitals and Clinics, as she discusses common types of female urinary incontinence seen in practice.